TPWA
CORT icon

TRUE Private Wealth Advisors’s Corcept Therapeutics CORT Stock Holding History

TRUE Private Wealth Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-17,410
Closed -$286K – 273
2018
Q1 		$286K Hold
17,410
– – 0.05% 187
2017
Q4 		$314K Buy
+17,410
New +$315K 0.05% 177

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TRUE Private Wealth Advisors's CORT Position: Q2 2018 in Review

TRUE Private Wealth Advisors sold out of Corcept Therapeutics (CORT) in Q2 2018, closing a stake of 17,410 shares — an estimated $286K sold.

TRUE Private Wealth Advisors first reported a position in CORT in Q4 2017 and held it in 2 quarters. The position peaked at $314K in Q4 2017. 215 funds tracked by Wall St. Rank hold CORT as of Q2 2018.

  • TRUE Private Wealth Advisors reported no remaining Corcept Therapeutics position as of Q2 2018 after selling out during the quarter.
  • TRUE Private Wealth Advisors sold 17,410 Corcept Therapeutics shares in Q2 2018, an estimated $286K.
  • TRUE Private Wealth Advisors first reported a position in Corcept Therapeutics in Q4 2017 and held it in 2 quarters.
  • TRUE Private Wealth Advisors's Corcept Therapeutics position peaked at $314K in Q4 2017.
  • 215 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2018.

Based on TRUE Private Wealth Advisors's 13F filing for Q2 2018, filed 13 Jul 2018.